Valuation: Insmed Incorporated

Market Cap 20.39B 18.21B 16.82B 15.25B 28.53B 1,936B 29B 202B 80.16B 1,014B 76.54B 74.91B 3,198B P/E 2026 *
-58.2x
P/E 2027 * 124x
Enterprise Value 19.79B 17.67B 16.33B 14.8B 27.68B 1,879B 28.14B 196B 77.79B 984B 74.28B 72.7B 3,103B EV / Sales 2026 *
10.9x
EV / Sales 2027 * 6.62x
Free-Float
99.49%
Yield 2026 *
-
Yield 2027 * -
1 day-1.76%
1 week-2.99%
Current month-18.18%
1 month-21.08%
3 months-13.05%
6 months-35.07%
Current year-46.34%
1 week 92.62
Extreme 92.625
97.88
1 month 92.62
Extreme 92.625
122.9
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.92
Extreme 21.92
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 10/09/2012
Director of Finance/CFO 45 31/01/2020
Chief Tech/Sci/R&D Officer 62 19/12/2019
Director TitleAgeSince
Chairman 75 16/06/2009
Chairman 57 08/11/2018
Director/Board Member 72 29/05/2014
Date Insider Type Main position Quantity % Market Cap. Importance
9/9/26 A Sell

Director

-25,000 0.0114%
8/17/26 A Sell

Director

-5,000 0.0023%
8/10/26 A Exercice

Chief Operating Officer

719,550 0.3320%
Change 5-day change 1-year change 3-year change Capi.($)
-1.76%-2.99%-41.67%+275.06% 20.39B
+2.41%+0.29%+42.02%+71.57% 64.69B
-0.15%+7.50%+11.01%+73.48% 54.78B
+0.57%+4.60%+10.07%+92.86% 53.49B
+0.37%+4.67%+27.03%+52.07% 45.98B
-1.21%+2.32%+21.80%+123.81% 42.94B
-0.37%+5.07%+249.91%+918.74% 40.08B
+0.05%+0.21%+18.26%+58.53% 33.52B
-0.38%+5.68%+36.43%+27.54% 23.67B
+1.19%-4.98%+29.01%-0.65% 23.97B
Average +0.07%+1.75%+40.39%+169.30% 40.35B
Weighted average by Cap. +0.28%+2.38%+43.06%+164.46%

Financials

2026 *2027 *
Net sales 1.81B 1.61B 1.49B 1.35B 2.53B 172B 2.57B 17.95B 7.11B 89.94B 6.79B 6.64B 284B 2.91B 2.6B 2.4B 2.18B 4.07B 276B 4.14B 28.89B 11.44B 145B 10.92B 10.69B 456B
Net income -334M -298M -276M -250M -468M -31.73B -475M -3.32B -1.31B -16.62B -1.25B -1.23B -52.41B 179M 160M 148M 134M 251M 17.02B 255M 1.78B 705M 8.92B 673M 659M 28.12B
Net Debt -603M -539M -498M -451M -844M -57.26B -858M -5.99B -2.37B -30B -2.26B -2.22B -94.59B -1.13B -1.01B -936M -849M -1.59B -108B -1.61B -11.27B -4.46B -56.45B -4.26B -4.17B -178B
Projected Income Statement - Annual - Insmed Incorporated
Logo Insmed Incorporated
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
Employees
1,664
Date Price Change Volume
23/10/26 $93.39 -1.76% 3,414,134
22/10/26 $95.06 +1.08% 3,099,798
21/10/26 $94.04 -1.70% 2,970,356
20/10/26 $95.67 +0.40% 2,612,666
19/10/26 $95.29 -1.02% 2,723,597
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Insmed Incorporated
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
93.39USD
Average target price
196.14USD
Spread / Average Target
+110.02%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Insmed Incorporated
  1. Stock Market
  2. Stocks
  3. INSM Stock